Research programme: anti-inflammatory phytochemicals - DiscoveryBioMed/ChromaDex
Latest Information Update: 07 Jul 2022
At a glance
- Originator DiscoveryBioMed
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dermatitis; Inflammation; Kidney disorders
Most Recent Events
- 05 Jul 2022 DiscoveryBioMed has been acquired by Eurofins Discovery
- 16 Jul 2016 No recent reports of development identified for research development in Dermatitis in USA
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in USA